Royalty Pharma Reports Q4 and Full Year 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Royalty Pharma (RPRX) Reports Q4 Revenue of $594 million
February 11, 2025 7:54 AM ESTRoyalty Pharma plc (NASDAQ: RPRX) reported Q4 revenue of $594 million, versus $596 million reported last year.
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty... More